Shionogi Completes ¥6 Billion Tablet Production Facility
This article was originally published in PharmAsia News
Executive Summary
Shionogi completed Nov. 11 the construction of a tablet manufacturing and packaging facility in Settsu, Osaka. With an investment of ¥6 billion, the new facility is built according to current good manufacturing practices required by U.S. FDA. The facility has a capacity of producing 550 million clinic trial and commercial drug tablets and one billion capsules each year. (Click here for more - Japanese language
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.